Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Spinocerebellar Degenerations 1 Rectal Neoplasms 1 Neoplasms 1 Locally Advanced Solid Tumor 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 38 Capecitabine 31 Oxaliplatin 30 Leucovorin 30 Radiotherapy 21 Irinotecan 20 Bevacizumab 15 Radiation 12 Cetuximab 12 pembrolizumab 9 Gemcitabine 7 trifluridine tipiracil drug combination 5 dehydroftorafur 5 cediranib 5 Radiotherapy, Intensity-Modulated 5 Folfox protocol 5 Erlotinib Hydrochloride 5 Cisplatin 5 Carboplatin 5 trametinib 4 Surgical Procedures, Operative 4 Paclitaxel 4 Neoadjuvant Therapy 4 Gene Expression Profiling 4 Cyclophosphamide 4 sargramostim 3 binimetinib 3 Trifluridine 3 Sorafenib 3 Pemetrexed 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Rectal Neoplasms × E7046 × Clear all

NCT03152370 2021-10-04

PRAER 1

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡